Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895845 | 0.95 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2895908 | 0.78 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5488505 | 0.72 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4234196 | 0.71 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2897122 | 0.71 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4335163 | 0.68 | GFER (0.37) | HPGDKDM4EALDH1A1MAPK10HSD17B10 | |
| SCHEMBL2895003 | 0.68 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2889941 | 0.67 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5478085 | 0.67 | ROCK2 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5481430 | 0.66 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-7576077-B2 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM5 | PSEN1 1636/4885PSEN2 1692/4885APH1B 3629/4885 |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | PSEN1 775/4885PSEN2 876/4885APH1B 3491/4885 |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM5 | PSEN1 1274/4885PSEN2 1240/4885APH1B 3296/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | PSEN1 786/4885PSEN2 902/4885APH1B 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.